News | August 30, 2025
Lilly's Verzenio scores first OS improvement in breast Cancer
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
